-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to CDE data on February 23, Chengdu Yuandong Biotech’s application for the imitation of phenylephrine hydrochloride injection 3 types of imitation listing has been accepted recently.
The product can be used to treat shock and maintain blood pressure during anesthesia, and it can also be used in the treatment room.
Upper tachycardia.
At present, only one company in the domestic market has been approved, and Yuandong is expected to become the second domestic company.
The product can be used to treat shock and maintain blood pressure during anesthesia, and it can also be used in the treatment room.
Upper tachycardia.
At present, only one company in the domestic market has been approved, and Yuandong is expected to become the second domestic company.
Figure 1: Registration status of Yuandong's Phenylephrine Hydrochloride Injection
Source: CDE official website
Figure 2: Overall sales of phenylephrine hydrochloride injection
Source: Comprehensive compilation of Minet's database
At present, only Shanghai Hefeng Pharmaceutical has obtained approval for phenylephrine hydrochloride injection on the domestic market, and no company has reviewed it yet .
This product is a national medical insurance category B product.
In 2019, the total sales in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) terminals, and China's urban physical pharmacies terminals totaled nearly 70 million yuan.
The main sales channels are urban public hospitals and County-level public hospitals.
This product is a national medical insurance category B product.
In 2019, the total sales in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) terminals, and China's urban physical pharmacies terminals totaled nearly 70 million yuan.
The main sales channels are urban public hospitals and County-level public hospitals.
Phenylephrine hydrochloride injection is Yuandong’s second injection to be marketed in 2021.
In January of this year, the company applied for the listing of 3 types of concentrated solutions for sodium valproate injection, which is expected to hit the country’s first imitation, valproic acid.
Sodium is the TOP1 variety of anti-epileptic drugs, and currently only powder injection products are used for injection.
In January of this year, the company applied for the listing of 3 types of concentrated solutions for sodium valproate injection, which is expected to hit the country’s first imitation, valproic acid.
Sodium is the TOP1 variety of anti-epileptic drugs, and currently only powder injection products are used for injection.
Source: Minet database, CDE official website
The review data statistics are as of February 22, 2021.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories.
The above sales are calculated based on the average retail price of the product at the terminal.
The above sales are calculated based on the average retail price of the product at the terminal.
According to CDE data on February 23, Chengdu Yuandong Biotech’s application for the imitation of phenylephrine hydrochloride injection 3 types of imitation listing has been accepted recently.
The product can be used to treat shock and maintain blood pressure during anesthesia, and it can also be used in the treatment room.
Upper tachycardia.
At present, only one company in the domestic market has been approved, and Yuandong is expected to become the second domestic company.
The product can be used to treat shock and maintain blood pressure during anesthesia, and it can also be used in the treatment room.
Upper tachycardia.
At present, only one company in the domestic market has been approved, and Yuandong is expected to become the second domestic company.
Figure 1: Registration status of Yuandong's Phenylephrine Hydrochloride Injection
Source: CDE official website
Figure 2: Overall sales of phenylephrine hydrochloride injection
Source: Comprehensive compilation of Minet's database
At present, only Shanghai Hefeng Pharmaceutical has obtained approval for phenylephrine hydrochloride injection on the domestic market, and no company has reviewed it yet .
This product is a national medical insurance category B product.
In 2019, the total sales in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) terminals, and China's urban physical pharmacies terminals totaled nearly 70 million yuan.
The main sales channels are urban public hospitals and County-level public hospitals.
This product is a national medical insurance category B product.
In 2019, the total sales in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) terminals, and China's urban physical pharmacies terminals totaled nearly 70 million yuan.
The main sales channels are urban public hospitals and County-level public hospitals.
Phenylephrine hydrochloride injection is Yuandong’s second injection to be marketed in 2021.
In January of this year, the company applied for the listing of 3 types of concentrated solutions for sodium valproate injection, which is expected to hit the country’s first imitation, valproic acid.
Sodium is the TOP1 variety of anti-epileptic drugs, and currently only powder injection products are used for injection.
In January of this year, the company applied for the listing of 3 types of concentrated solutions for sodium valproate injection, which is expected to hit the country’s first imitation, valproic acid.
Sodium is the TOP1 variety of anti-epileptic drugs, and currently only powder injection products are used for injection.
Source: Minet database, CDE official website
The review data statistics are as of February 22, 2021.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories.
The above sales are calculated based on the average retail price of the product at the terminal.
The above sales are calculated based on the average retail price of the product at the terminal.
According to CDE data on February 23, Chengdu Yuandong Biotech’s application for the imitation of phenylephrine hydrochloride injection 3 types of imitation listing has been accepted recently.
The product can be used to treat shock and maintain blood pressure during anesthesia, and it can also be used in the treatment room.
Upper tachycardia.
At present, only one company in the domestic market has been approved, and Yuandong is expected to become the second domestic company.
The product can be used to treat shock and maintain blood pressure during anesthesia, and it can also be used in the treatment room.
Upper tachycardia.
At present, only one company in the domestic market has been approved, and Yuandong is expected to become the second domestic company.
Figure 1: Registration status of Yuandong's Phenylephrine Hydrochloride Injection
Source: CDE official website
Figure 2: Overall sales of phenylephrine hydrochloride injection
Source: Comprehensive compilation of Minet's database
At present, only Shanghai Hefeng Pharmaceutical has obtained approval for phenylephrine hydrochloride injection on the domestic market, and no company has reviewed it yet .
This product is a national medical insurance category B product.
In 2019, the total sales in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) terminals, and China's urban physical pharmacies terminals totaled nearly 70 million yuan.
The main sales channels are urban public hospitals and County-level public hospitals.
Enterprise enterprise enterprise hospital hospital hospital pharmacy pharmacy pharmacyThis product is a national medical insurance category B product.
In 2019, the total sales in China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) terminals, and China's urban physical pharmacies terminals totaled nearly 70 million yuan.
The main sales channels are urban public hospitals and County-level public hospitals.
Phenylephrine hydrochloride injection is Yuandong’s second injection to be marketed in 2021.
In January of this year, the company applied for the listing of 3 types of concentrated solutions for sodium valproate injection, which is expected to hit the country’s first imitation, valproic acid.
Sodium is the TOP1 variety of anti-epileptic drugs, and currently only powder injection products are used for injection.
In January of this year, the company applied for the listing of 3 types of concentrated solutions for sodium valproate injection, which is expected to hit the country’s first imitation, valproic acid.
Sodium is the TOP1 variety of anti-epileptic drugs, and currently only powder injection products are used for injection.
Source: Minet database, CDE official website
The review data statistics are as of February 22, 2021.
If there are any errors or omissions, please correct me.
If there are any errors or omissions, please correct me.
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories.
The above sales are calculated based on the average retail price of the product at the terminal.
The above sales are calculated based on the average retail price of the product at the terminal.
